Foghorn Therapeutics Inc.
FHTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001822462
No open-market purchases or sales by Foghorn Therapeutics Inc. insiders were filed in the last 90 days; 102 institutions reported holding it in 13F filings for Q2 2026, worth $219.2M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Foghorn Therapeutics Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Foghorn Therapeutics Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Parshall B Lynne | Director | – | Jun 25, 2026 | 1 |
| Gill Simba | Director | 34,061 | Jun 25, 2026 | 1 |
| Smith Ian F | Director | – | Jun 25, 2026 | 1 |
| Lynch Thomas J. Jr. | Director | – | Jun 25, 2026 | 1 |
| Cole Douglas G. | Director | – | Jun 25, 2026 | 1 |
| Biller Scott | Director | – | Jun 25, 2026 | 1 |
| Mendelsohn Michael | Director | – | Jun 25, 2026 | 1 |
| Duty Stuart | Director | – | Jun 25, 2026 | 1 |
| Gallagher Neil | Director | – | Jun 25, 2026 | 1 |
| Gottschalk Adrian | Chief Executive Officer | 270,912Indirect | Apr 13, 2026 | 2 |
| Maynard Ryan D | Chief Financial Officer | – | Feb 24, 2026 | 1 |
| Cardama Alfonso Quintas | Chief Medical Officer | – | Feb 2, 2026 | 1 |
| Bellon Steven F. | Chief Scientific Officer | 101,957 | Feb 2, 2026 | 1 |
| LaCascia Michael | Chief Legal Officer | – | Feb 2, 2026 | 1 |
| Costa Carlos | Chief People Officer | 0 | Feb 2, 2026 | 1 |
| Rivkin Anna | Chief Business Officer | – | Feb 2, 2026 | 1 |
| Afeyan Noubar | Director, 10% Owner | – | Jan 15, 2026 | 1 |
| Flagship Pioneering, LLC | Director, 10% Owner | – | Jan 15, 2026 | 1 |
| Flagship Ventures Fund V, L.P. | Director, 10% Owner | – | Jan 15, 2026 | 1 |
| Flagship Ventures Opportunities Fund I, L.P. | Director, 10% Owner | – | Jan 15, 2026 | 1 |
| Flagship Ventures Fund V General Partner LLC | Director, 10% Owner | – | Jan 15, 2026 | 1 |
| Flagship Ventures Opportunities Fund I General Partner LLC | Director, 10% Owner | – | Jan 15, 2026 | 1 |
| Flagship Pioneering Special Opportunities Fund II, L.P. | Director, 10% Owner | – | Jan 15, 2026 | 1 |
| Flagship Pioneering Fund VII, L.P. | Director, 10% Owner | – | Jan 15, 2026 | 1 |
| Flagship Pioneering Fund VII General Partner LLC | Director, 10% Owner | – | Jan 15, 2026 | 1 |
| Flagship Pioneering Special Opportunities Fund II General Partner LLC | Director, 10% Owner | – | Jan 15, 2026 | 1 |
| Humer Kristian | Chief Financial Officer | – | Nov 17, 2025 | 1 |
| Koppel Adam | Director | – | Dec 30, 2024 | 0 |
| Cavalie Fanny | Chief Strategy/Bus Ops Officer | 75,992 | Jun 24, 2024 | 0 |
| Reine Allan | Chief Financial Officer | 53,784 | Jan 17, 2024 | 0 |
| Agresta Samuel | Chief Medical Officer | 0 | Sep 13, 2023 | 0 |
| Kadoch Cigall | Director | 295,000 | Sep 2, 2022 | 0 |
| Decicco Carl | Chief Scientific Officer | 362,707 | Dec 13, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 24, 2024 (view filing) | Sep 20-23 | 4 days | Costa CarlosChief People Officer | SSale | −36.6K | $10.04 | −$367.7K | −100.0%0 after | 2 lots10b5-1 |
| Sep 20, 2024 (view filing) | Sep 18 | 2 days | Costa CarlosChief People Officer | SSale | −11.6K | $10.05 | −$116.3K | −100.0%0 after | 10b5-1 |
| Sep 18, 2024 (view filing) | Sep 16-17 | 2 days | Costa CarlosChief People Officer | SSale | −10.7K | $10.04 | −$107.1K | −100.0%0 after | 2 lots10b5-1 |
| Sep 11, 2024 (view filing) | Sep 9 | 2 days | Bellon Steven F.Chief Scientific Officer | SSale | −20.0K | $9.50 | −$190.0K | −16.4%102.0K after | 10b5-1 |
| May 24, 2024 (view filing)5:05 PM ET | May 22 | 2 days | Afeyan Noubar and 3 others10% Owner | PPurchase | +3.63M | $5.51 | +$20.0M | –1.81M after | Derivative2 lots |
| Mar 12, 2024 (view filing) | Mar 11 | 1 day | Cavalie FannyChief Strategy/Bus Ops Officer | SSale | −11.0K | $6.56 | −$72.2K | −12.6%76.0K after | |
| Aug 18, 2023 (view filing) | Aug 16 | 2 days | Agresta SamuelChief Medical Officer | SSale | −311.3K | $8.25 | −$2.57M | −100.0%0 after |